CAMBRIDGE, Mass. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will present at the
Company Integrates Operational Oversight with Dr. Suri’s Expertise in Immunology CAMBRIDGE, Mass. , Oct. 07, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE) a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate
CAMBRIDGE, Mass. , Oct. 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it is scheduled to present at the
Change represents evolving board capabilities as Cue Biopharma enters next stage of its corporate development CAMBRIDGE, Mass. , Oct. 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE) a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to
CAMBRIDGE, Mass. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will present at the
CAMBRIDGE, Mass. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will deliver a poster
CAMBRIDGE, Mass. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will host a conference call
CAMBRIDGE, Mass. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will present at the
Initiated patient dosing in Phase 1 clinical study of lead program CUE-101 in head and neck squamous cell carcinoma (HNSCC) Extended cash runway with $11.9 million from at-the-market equity offering in Q3 Promoted Dr. Anish Suri to the role of president and chief scientific officer CAMBRIDGE, Mass.
Presentation Highlights Recent Platform Development Providing the Potential to Readily Exchange T cell Epitopes to Target Diverse T cell Populations CAMBRIDGE, Mass. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel